A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Significant progress has been achieved in treating patients with onco-hematological diseases, including chronic myeloid leukemia (CML). This is primarily associated with the development of targeted therapy involving tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, dasatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopina, Nataliia, Dmytrenko, Iryna, Hamov, Dmytro, Lopin, Dmytro, Dyagil, Iryna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270100/
https://www.ncbi.nlm.nih.gov/pubmed/35812557
http://dx.doi.org/10.7759/cureus.25766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270100/
https://www.ncbi.nlm.nih.gov/pubmed/35812557
http://dx.doi.org/10.7759/cureus.25766

Ejemplares similares